| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
The metabolism primarily occurs in the liver. Enzymatic activity capable of hydrolyzing phentiromid has also been found in the normal small intestine. |
|---|---|
| Additional Infomation |
Bentiromide is a dipeptide formed by the condensation of N-benzoyl-L-tyrosine and 4-aminobenzoic acid. It is a non-invasive test for screening pancreatic exocrine insufficiency and can also be used to monitor the effectiveness of pancreatic supplementation therapy. Bentiromide is administered orally and assesses the activity of pancreatic chymotrypsin secreted by the pancreas by detecting the excretion of 4-aminobenzoic acid and its metabolites in urine. It can be used as a diagnostic agent, indicator, and reagent. Bentiromide is a dipeptide used in the Bentiromide test, a screening test for assessing pancreatic exocrine function and monitoring the effectiveness of pancreatic supplementation therapy. Bentiromide is usually administered orally. Headache and gastrointestinal discomfort have been reported after using Bentiromide. Currently, Bentiromide is not marketed in the United States and Canada. Drug Indications For screening exocrine pancreatic insufficiency and monitoring the efficacy of pancreatic supplementation therapy. Mechanism of Action Bentiromide is a peptide drug that is broken down by chymotrypsin in the pancreas. Following oral administration, the amount of unmetabolized bentimolol excreted in urine can determine pancreatic function adequacy.
Pharmacodynamics Benttimolol is a peptide drug used to screen for exocrine pancreatic insufficiency and monitor the efficacy of pancreatic replacement therapy. The amount of para-aminobenzoic acid and its metabolites excreted in urine is a quantitative indicator of pancreatic chymotrypsin secretory activity. |
| Molecular Formula |
C23H20N2O5
|
|---|---|
| Molecular Weight |
404.42
|
| Exact Mass |
404.137
|
| CAS # |
37106-97-1
|
| PubChem CID |
6957673
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.367g/cm3
|
| Boiling Point |
797.1ºC at 760mmHg
|
| Melting Point |
240-242
241 °C |
| Flash Point |
435.9ºC
|
| Index of Refraction |
1.678
|
| LogP |
3.534
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
588
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC=1C=CC(=CC1)C[C@@H](C(NC2=CC=C(C(O)=O)C=C2)=O)NC(C3=CC=CC=C3)=O
|
| InChi Key |
SPPTWHFVYKCNNK-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1
|
| Chemical Name |
4-[[(2S)-2-benzamido-3-(4-hydroxyphenyl)propanoyl]amino]benzoic acid
|
| Synonyms |
Bentiromide Bentiromidum Bentiromido
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~618.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4727 mL | 12.3634 mL | 24.7268 mL | |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL | |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.